Study of Modzatinib (ATI-2138) in Adult Participants With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies
Trial details
- Registry ID
- NCT07935590
- Drugs studied
- Modzatinib
TrialRedline tracks 9 clinical trials sponsored by Aclaris Therapeutics, Inc.: 9 Phase 2.
Company identity checked against sources
Names as written in the registry records.
NCT07935590 · Aclaris Therapeutics, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT07011706 · Aclaris Therapeutics, Inc.
Before: Estimated. After: Actual.
Before: Aug 2026. After: 21 Sep 2026.
NCT05279417 · Aclaris Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of patients achieving ACR20 at Week 12 Time frame: Baseline to Week 12. After: Measure: Percentage of Participants Achieving ACR20 at Week 12 Description: Participants achieving American College of Rheumatology (ACR) 20 (responders) were defined as having ≥20% improvement in both the number of swollen and tender joints (66/68 joint counts) and ≥20% improvement in ≥3 of the following 5 measures: Patient's Global Assessment of Disease Activity (VAS), Patient's Assessment of Arthritis Pain (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician's Global Assessment of Disease Activity (VAS), and acute phase reactant as measured by hsCRP. Model-based estimates and 95% confidence intervals (CIs) were produced. Time frame: Week 12.
NCT07011706 · Aclaris Therapeutics, Inc.
Before: Estimated. After: Actual.
Before: 96 participants (planned). After: 110 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT05216224 · Aclaris Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Efficacy measured as the change from Baseline in inflammatory nodule/abscess count at Week 12.. After: Measure: Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 12.